Beam Therapeutics(us:BEAM)

    28.44

    -1.96%

    Updated on 2024-12-23

    Open:29.25
    Close:28.44
    High:29.52
    Low:28.38
    Pre Close:29.01
    Volume:370505.00
    Amount:10.69M
    Turnover:0.45%
    Shares:82.81M
    MarketCap:2.36B

    About Beam Therapeutics Company

    Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

    Company Name: Beam Therapeutics
    Company Address: 238 Main Street,9th floor
    Employees: 436
    Fiscar Year: 12-31
    IPO Date: 2020-02-06
    CIK: 1745999

    View all SEC Filings

    About

    Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
    Address:238 Main Street,9th floor

    Market Movers